Krsnaa Diagnostics Ltd Q2 FY26 – ₹2,060 Mn Revenue, ₹602 Mn EBITDA, ₹239 Mn PAT. The PPP King of India’s Healthcare Check-Up Saga.
1. At a Glance
Ladies and gentlemen, say hello to Krsnaa Diagnostics Ltd, the “Doctor Babu” of Indian diagnostics, who runs more MRI scanners than most districts have ambulances. At ₹724 per share and a market cap of ₹2,350 crore, the company’s recent quarter results (Q2 FY26) screamed both growth and governance drama. With revenue of ₹2,060 million, EBITDA ₹602 million, and PAT ₹239 million, the Pune-based PPP (Public-Private Partnership) ninja continues to make money out of government tenders faster than your local politician can inaugurate a hospital wing.
Still, the script isn’t without tension. Payment delays from government contracts (hello, 68-day receivables) and a tax demand of ₹513.86 million in H1 FY26 mean that while the radiology machines hum, the CFO’s heart rate monitor is beeping steadily too.
The stock trades at a P/E of 27.5, comfortably below the industry’s 36x — not cheap, but fair for a company that runs diagnostics for half of Bharat. The return profile shows ROCE at 12.5% and ROE at 9.3%, with debt-to-equity at a modest 0.3x. So yes, the balance sheet looks fine — until you realize it’s built mostly on government IOUs and diagnostic dreams.
Three months return? A depressing -14.6%. One year? -22.9%. Investors clearly want results faster than a CBC report. But here’s the kicker: Krsnaa’s affordable test prices (60–80% lower than private peers) make it the Aadhaar-enabled discount machine of Indian diagnostics.
2. Introduction – The PPP Poster Child with a Pulse
If India’s healthcare infrastructure were a Bollywood script, Krsnaa Diagnostics would be that underrated character actor holding the plot together. Not flashy like Dr Lal PathLabs or glamorous like Metropolis Healthcare — but absolutely everywhere.
From district hospitals in Rajasthan to medical colleges in Bihar, Krsnaa has built a nationwide grid of 5,100+ diagnostic centers, proving that “Make in India” can also mean “Scan in India.” The company’s model thrives on partnerships — mainly with governments — to deliver high-quality diagnostic services in regions where Apollo Diagnostics would rather not send a courier.
The result? A PPP empire covering 18 states and union territories, performing 1.5 lakh CT/MRI scans per month and processing 6 lakh X-rays monthly. The sheer scale of its operations is both its moat and migraine: it wins 78% of all tenders it bids for, but collecting payments on time from sarkari health departments remains trickier than diagnosing an Indian politician’s net worth.
The latest quarter (Q2 FY26) showed that growth is still ticking, with a 5.78% PAT jump QoQ and revenues touching ₹183 crore. But it’s not all smooth imaging — the taxman’s ₹513 crore demand and occasional management shake-ups (including a CBO resignation in April 2025) add a tinge of drama to the pathology playbook.
So, is Krsnaa Diagnostics a savior of India’s affordable healthcare or a high-volume hustler with thin margins and delayed payments? Let’s dissect this patient.
3. Business Model – WTF Do They Even Do?
Imagine a lab that can do everything from X-rays in Jharkhand to MRIs in Mumbai — and still charge less than your local chemist’s electricity bill. That’s Krsnaa Diagnostics.
The business operates across three major segments:
Radiology (57% of FY24 revenue): MRI, CT, and X-ray centers across India — 178 MRI centers and over 1,400 tele-radiology hubs. They handle over 1.5 lakh scans monthly.
Pathology (43% of FY24 revenue): 121 processing labs, 3,423 collection centers — and an ambition to flip the mix to 60:40 (pathology: radiology) in two years.
Teleradiology: The digital backbone. Reports from rural CT centers are transmitted to specialists sitting miles away. Essentially, cloud computing for human organs.
Now, the genius — or madness — of Krsnaa’s business lies in its PPP model. Governments provide space, Krsnaa installs equipment, runs operations, and earns per test — but payments depend on bureaucratic efficiency. So yes, while others run for retail customers, Krsnaa runs on government goodwill and PowerPoint presentations.
Recently, the company has started branching into retail diagnostics, targeting 500 franchise “Krsnaa Brand Associates (KBAs)” by FY26. A smart move — because when government payments lag, retail cash flow can keep the ECG flatline-free.
And just when you think it’s all organic, Krsnaa went and acquired Apulki Healthcare for ₹31.25 crore, grabbing exclusive diagnostic rights in a PPP hospital chain focused on cardiac and cancer care. That’s a 30-year revenue visibility deal — rare in diagnostics, and probably longer than most Indian marriages.
4. Financials Overview
Metric
Latest Qtr (Sep ’25)
YoY Qtr (Sep ’24)
Prev Qtr (Jun ’25)
YoY %
QoQ %
Revenue (₹ Cr)
183
179
176
2.23%
3.98%
EBITDA (₹ Cr)
58
52
50
11.5%
16.0%
PAT (₹ Cr)
23.2
22
20
5.5%
16.0%
EPS (₹)
7.16
6.80
6.03
5.3%
18.7%
Witty commentary: The numbers are less diagnostic and more predictable — slow but steady. Think of it as the Hemoglobin level of an average Indian — not ideal, but functional. Krsnaa’s EBITDA margin of 32% is the envy of hospital chains, and its PAT growth of 16% QoQ suggests operational improvement despite bureaucratic hiccups.
5. Valuation Discussion – The Fair Value Range
Method 1: P/E Based Valuation
EPS (TTM): ₹26.4
Industry Average P/E: 36.4
Krsnaa’s Current P/E: 27.5 Fair Value Range (P/E Method): ₹950 – ₹1,050 (educational purpose only)
Method 2: EV/EBITDA Approach
EV = ₹2,504 Cr
EBITDA (FY25): ₹209 Cr
EV/EBITDA = 12x If re-rated to industry’s 15x EV/EBITDA → EV = ₹3,135
